

# *Microbiome and biofilm* 101

Professor Paul Johnson

Infectious Diseases Department


Austin Health & University of Melbourne

Microbiome:

*“the collection of cells, genes,  
and metabolites from the  
bacteria, eukaryotes, and  
viruses that  
inhabit the human body.....”*




# Relative abundance




## Human microbiome

- 1) Stable by site over time
- 2) Stable in one person over time; differs between people
- 3) Diet and age affect it
- 4) Some microbiome types linked to disease but big variation between people with same condition (eg obesity, IBD)


- | Bacteria:   | Fungi:   |
|---|--|
|  <i>Propionibacterium</i> spp. |  <i>Malassezia</i> spp. |
|  <i>Staphylococcus</i> spp.    |  Virus                  |
|  <i>Corynebacterium</i> spp.   |  |



<https://www.nature.com/articles/nrmicro.2017.157>



<https://www.nature.com/articles/nrmicro.2017.157>



## The human skin microbiome

Allyson L. Byrd<sup>1-4</sup>, Yasmine Belkaid<sup>5,6</sup> and Julia A. Segre<sup>1</sup>

**Colonization resistance**  
A mechanism where commensal microorganisms prevent the colonization of harmful microorganisms.

**Figure 1 | Skin microbial communities are shaped by physiological characteristics and the individual.** Four sites are shown to represent major microenvironments of the skin: glabella (also known as the forehead) sebaceous (oily); antecubital fossa (moist); volar forearm (dry); and toe web space (foot). Pie charts represent consensus relative abundances of the kingdom, fungi and bacteria across healthy adults<sup>2</sup>. The bacterial species *Propionibacterium acnes* and *Staphylococcus epidermidis* and eukaryotic DNA viruses are displayed as bar charts for four representative individuals to highlight how individuality shapes these communities<sup>25</sup>. For kingdom, fungi, bacteria and virus relative abundance plots, major taxa colours are identified in the legend. Unlabelled colours may be grouped as 'Other'. For the *P. acnes* and *S. epidermidis* bar charts, similar colours represent closely related strains.





Figure 3 | **Skin commensal interactions with *Staphylococcus aureus*.** Skin microbial communities are shaped by interactions between organisms and with the host. In the skin, many interactions between commensals and *Staphylococcus aureus* have been identified. Antibiotics produced by coagulase-negative *Staphylococcus* and specifically by *Staphylococcus lugdunensis* prohibit colonization of *S. aureus*. Also, *Staphylococcus epidermidis* can inhibit *S. aureus* biofilm formation with production of the serine protease glutamyl endopeptidase (Esp). Moreover, when Esp-expressing *S. epidermidis* induces keratinocytes to produce antimicrobial peptides via immune cell signalling, *S. aureus* is effectively killed. In addition, *Staphylococcus hominis*-produced lantibiotics synergize with human antimicrobial peptide LL-37 to decrease *S. aureus* colonization. In contrast to inhibiting *S. aureus*, *Propionibacterium acnes* produces a small molecule, coproporphyrin III, that promotes *S. aureus* aggregation and biofilm formation.



**Fig. 2** Cutaneous immunity is differentially regulated by commensal and pathogenic microorganisms through modulation of Perforin-2. **a** Colonization of the wound with commensal bacteria may promote wound healing by inducing antimicrobial proteins such as Perforin-2,

thus stimulating a protective immune response against pathogenic bacteria. **b** Wound infection with pathogenic bacteria results in Perforin-2 suppression in both hematopoietic and nonhematopoietic cells and inhibition of healing

# Biofilms:

*“self-constructed accumulations of microorganisms that produce a matrix of extracellular biopolymers ...The collective behaviour of bacteria within biofilms promotes communication and interaction to ensure propagation and survival.”*

<https://www.nature.com/articles/s41579-023-00905-2>

[nature](#) > [nature reviews microbiology](#) > [review articles](#) > [article](#)

Review Article | [Published: 31 May 2023](#)

## **Drug delivery strategies for antibiofilm therapy**

[Victor Choi](#), [Jennifer L. Rohn](#), [Paul Stoodley](#), [Dario Carugo](#) & [Eleanor Stride](#) 

[Nature Reviews Microbiology](#) **21**, 555–572 (2023) | [Cite this article](#)


4506 Accesses | 8 Citations | 33 Altmetric | [Metrics](#)

# Plastic Surgery Relevance of Biofilm Infection

- Bacterial biofilm infection not routinely detected using standard microbiologic techniques
- Bacteria in biofilm state are recalcitrant to antimicrobials
- Bacteria in biofilm evade host immune response
- Biofilm infection recurs after debridement
- Bacteria on biofilm state express or induce expression of proteins that degrade soft tissue
- Biofilm infection compromises skin barrier function

Barker JC, Khansa I, Gordillo GM. A Formidable Foe is Sabotaging Your Results: What You Should Know About Biofilms and Wound Healing, *Plastic & Recon Surg* 2017; 139(5): 1184e-1194e

**Fig. 2: Challenges associated with treating biofilm-associated infections.**




Drug delivery strategies for antibiofilm therapy

<https://www.nature.com/articles/s41579-023-00905-2>

Victor Choi<sup>1</sup>, Jennifer L. Rohm<sup>1</sup>, Paul Stoodley<sup>1\*</sup>, Dario Canga<sup>2</sup> & Eleanor Stride<sup>1,3</sup>

### Biofilm Management in Wound Care

Chandan K. Sen, PhD,<sup>1,2,3</sup> Sashwati Roy, PhD,<sup>1,2,3</sup> Sromita S. Mathew, Steiner, PhD,<sup>1,2,3</sup> and Gayle M. Gorsillo, MD<sup>1,2,3</sup>




**Phagocytes, *P aeruginosa*, *A baumannii*, biofilm matrix/EPS**

Figure 1. 3D imaging of biofilm and host immune cells.

<https://pubmed.ncbi.nlm.nih.gov/34398099/>

# SEM is the way to prove biofilm, not clinically available; biofilms not detectable visually



Day 14

## Summary

- Biofilm infection is extremely common in chronic wounds
- Scanning electron microscopy is the gold standard to diagnose biofilm infection
- There are multiple approaches to treat biofilm infection
  - none have been rigorously tested in clinical trials
  - Debridement and topical +/- systemic antimicrobials are the gold standard
- Studies to evaluate therapeutic efficacy of biofilm inhibitors must be done in live animals/human subjects to include host vs. pathogen immune responses

[Plast Reconstr Surg](#), Author manuscript; available in PMC 2022

Aug 1.

Published in final edited form as:

[Plast Reconstr Surg](#). 2021 Aug 1; 148(2): 275e-288e.

doi: [10.1097/PRS.00000000000008142](#)


PMCID: PMC8439557

NHMSID: NHMS1686443

PMID: 34398099

Biofilm Management in Wound Care

Chandan K. Sen, PhD,<sup>1,2,3</sup> Sashwati Roy, PhD,<sup>1,2,3</sup> Shomita S. Mathew-Steiner, PhD,<sup>1,2,3</sup> and Gayle M. Gordillo, MD<sup>1,2,3</sup>



**Figure 4.**

Levels of Evidence modified for Anti-biofilm strategies.

[Plast Reconstr Surg](#), Author manuscript; available in PMC 2022

PMCID: PMC8439557

Aug 1.

NIHMSID: NIHMS1686443

Published in final edited form as:

PMID: [34398099](#)

[Plast Reconstr Surg](#). 2021 Aug 1; 148(2): 275e-288e.

doi: [10.1097/PRS.00000000000008142](#)

## Biofilm Management in Wound Care

[Chandan K. Sen](#), PhD,<sup>1,2,3</sup> [Sashwati Roy](#), PhD,<sup>1,2,3</sup> [Shomita S. Mathew-Steiner](#), PhD,<sup>1,2,3</sup> and [Gayle M. Gordillo](#), MD<sup>1,2,3</sup>

# Summary

- Microbiome, “life-long (mostly) friendly tenants” discoverable because of major advances in culture independent methods
  - Masses of data, not much knowledge (yet) applicable to chronic wounds, clinical microbiome tests not yet available, ...
- Biofilm – “defended, organized enemy camp”.
  - Likely present in most chronic wounds but hard to detect, likely prolongs time/completeness of healing, hard to remove...